Key statistics
On Monday, ACADIA Pharmaceuticals Inc (0A4W:LSE) closed at 14.64, 0.47% above its 52-week low of 14.57, set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 14.64 |
Low | 14.64 |
Bid | -- |
Offer | -- |
Previous close | 15.05 |
Average volume | 1.18k |
---|---|
Shares outstanding | 165.88m |
Free float | 164.99m |
P/E (TTM) | 83.28 |
Market cap | 2.50bn USD |
EPS (TTM) | 0.1813 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 18:42 BST.
More ▼
Press releases
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Ryan Reynolds Announces More to Parkinson’s® Campaign
- Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
More ▼